Sequencing HER2-Directed Therapies in NSCLC
Drs. Joshua Sabari, Alfredo Addeo, Julia Rotow, and Helena Yu examine evolving treatment sequencing strategies for HER2-mutant non-small cell lung cancer (NSCLC...
View MoreESMO 2026 NSCLC Roundtable
Overcoming Resistance in HER2-Mutant NSCLC
Drs. Joshua Sabari, Alfredo Addeo, Julia Rotow, and Helena Yu highlight emerging resistance mechanisms to HER2-directed therapies in non-small cell lung cancer ...
View More
Latest Conference News
DESTINY-Lung04: Frontline T-DXd Efficacy and ILD Management in HER2-Mutant NSCLC
Drs. Joshua Sabari, Alfredo Addeo, Julia Rotow, and Helena Yu discuss findings from DESTINY-Lung04, which evaluated trastuzumab deruxtecan (T-DXd) against chemo...
View More
HER2-Mutant NSCLC: Frontline Treatment Options and CNS Activity
Drs. Joshua Sabari, Alfredo Addeo, Julia Rotow, and Helena Yu examine emerging frontline treatment options for HER2-mutant non-small cell lung cancer (NSCLC), f...
View More
HER2 Alterations in NSCLC: Mutations, Testing, and Treatment Selection
Drs. Joshua Sabari, Alfredo Addeo, Julia Rotow, and Helena Yu examine the different types of HER2 alterations in non-small cell lung cancer (NSCLC), including m...
View More
ESMO 2026: KRASCENDO-1 and SAFFRON Advance Targeted Therapy in NSCLC
Drs. Joshua Sabari, Alfredo Addeo, Julia Rotow, and Helena Yu review practice-changing data from ESMO 2026, highlighting advances in targeted therapy for KRAS G...
View More